Novel lung cancer biomarker (liph)

Patent metadata

Field	Value
Publication number	US-2016369349-A1
Application number	US-201414901578-A
Country	US
Kind code	A1
Filing date	Mar 18, 2014
Priority date	Jun 28, 2013
Publication date	Dec 22, 2016
Grant date	—

Abstract

[Problem to be Solved] To provide a new lung-cancer biomarker, which has a high detection efficiency and determines the type (histological type) of lung cancer.
[Solution] LIPH (lipase, member H), which is enhanced in a plurality of lung cancer-derived cell lines compared to that in normal lung-derived epithelial cells and is almost surely expressed highly in lung cancer.

First claim

1 - 15 . (canceled)

16 . A method for detecting a cancer comprising:
(i) obtaining a sample from a subject and a healthy volunteer; (ii) determining at least one of the following cancer markers:
(a) an amount of a polypeptide encoded by LIPH gene in the sample from the subject and an amount of the polypeptide in the healthy volunteer,
(b) an amount of mRNA encoding LIPH in the sample from the subject and an amount of the mRNA encoding LIPH in the healthy volunteer, and
(c) an amount of a polypeptide encoded by LIPH gene in the sample from the subject and the healthy volunteer; and
(iii) comparing:
(1) the amount of the cancer marker in the sample from the subject and amount of the cancer marker in the healthy volunteer as determined in (a) or (b), or
(2) the amount of the polypeptide encoded by LIPH gene in the sample from the subject and the healthy volunteer as determined in (c).

17 . The method of claim 16 , wherein the cancer is lung cancer or esophageal cancer.

18 . A labeled cancer detection probe having a sequence complementary to the sequence represented by SEQ ID NO: I or to a sequence in which one to several nucleotides are deleted, substituted, and/or added in the sequence.

19 . The cancer detection probe of claim 18 , wherein the cancer is lung cancer or esophageal cancer.

20 . A method for detecting a cancer comprising:
(i) obtaining a sample from a subject and a healthy volunteer; (ii) preparing:
(a) cDNA from mRNA of LIPH gene in the sample from the subject and the healthy volunteer using at least a primer comprising consecutive 15 or more nucleotides in the sequence of LIPH gene, or
(b) cDNA from mRNA of LIPH gene in the sample from the subject and the healthy volunteer using at least a primer comprising any consecutive 15 or more nucleotides in the sequence represented by SEQ ID NO: I or a sequence in which one or several nucleotides are deleted, substituted, and/or added in the sequence;
(iii) determining an amount of cDNA of the LIPH gene in the sample from the subject and the healthy volunteer; and (iv) comparing the amount of the cDNA of LIPH gene in the sample from the subject and the healthy volunteer.

21 . The method of claim 20 , wherein the cancer is lung cancer or esophageal cancer.

22 . A method for detecting a cancer comprising:
(i) obtaining a sample from a subject and a healthy volunteer, (ii) contacting an antibody(ies) to LIPH with the sample from the subject and the healthy volunteer.

23 . The method of claim 22 , wherein the cancer is lung cancer or esophageal cancer.

24 . The method of claim 22 , wherein the antibody(ies) is a monoclonal antibody.

25 . The method of claim 23 , wherein the antibody is a monoclonal antibody(ies).

26 . A lung cancer detection kit comprising:
(i) a primer comprising consecutive 15 or more nucleotides in the sequence of LIPH; (ii) a primer comprising any consecutive 15 or more nucleotides in the sequence represented by SEQ ID NO: I or a sequence in which one or several nucleotides are deleted, substituted, and/or added in the sequence; or (iii) an antibody(ies) to LIPH, or monoclonal antibody(ies) to LIPH.

Assignees

• Eiken Chemical
• Nat Inst Advanced Ind Science & Tech

Inventors

• Seki Yasuhiro
• Shibata Norio
• Asashima Makoto
• Kurisaki Akira

Classifications

• G01N33/5752

  of the lungs · CPC title

• G01N33/57585

  involving compounds identifiable in body fluids · CPC title

• G01N33/57557

  of other specific parts of the body, e.g. brain · CPC title

• C12Q1/6886 Primary

  for cancer (immunoassay for cancer G01N33/575) · CPC title

• C12Q2600/00

  Oligonucleotides characterized by their use · CPC title